医学
淋巴瘤
移植
干细胞
化疗
免疫学
T细胞
胃肠病学
内科学
骨髓
造血干细胞移植
肿瘤科
免疫系统
生物
遗传学
作者
Lauren P. McLaughlin,Rayne Helen Rouce,Stephen M Gottschalk,Vicky Torrano,George Carrum,Meng‐Fen Wu,Fahmida Hoq,Bambi Grilley,Andrea M. Marcogliese,Patrick J. Hanley,Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Helen Elisabeth Heslop,Catherine M. Bollard
出处
期刊:Blood
[Elsevier BV]
日期:2018-09-27
卷期号:132 (22): 2351-2361
被引量:76
标识
DOI:10.1182/blood-2018-07-863654
摘要
Autologous T cells targeting Epstein-Barr virus (EBV) latent membrane proteins (LMPs) have shown safety and efficacy in the treatment of patients with type 2 latency EBV-associated lymphomas for whom standard therapies have failed, including high-dose chemotherapy followed by autologous stem-cell rescue. However, the safety and efficacy of allogeneic donor-derived LMP-specific T cells (LMP-Ts) have not been established for patients who have undergone allogeneic hematopoietic stem-cell transplantation (HSCT). Therefore, we evaluated the safety and efficacy of donor-derived LMP-Ts in 26 patients who had undergone allogeneic HSCT for EBV-associated natural killer/T-cell or B-cell lymphomas. Seven patients received LMP-Ts as therapy for active disease, and 19 were treated with adjuvant therapy for high-risk disease. There were no immediate infusion-related toxicities, and only 1 dose-limiting toxicity potentially related to T-cell infusion was seen. The 2-year overall survival (OS) was 68%. Additionally, patients who received T-cell therapy while in complete remission after allogeneic HSCT had a 78% OS at 2 years. Patients treated for B-cell disease (n = 10) had a 2-year OS of 80%. Patients with T-cell disease had a 2-year OS of 60%, which suggests an improvement compared with published posttransplantation 2-year OS rates of 30% to 50%. Hence, this study shows that donor-derived LMP-Ts are a safe and effective therapy to prevent relapse after transplantation in patients with B cell- or T cell-derived EBV-associated lymphoma or lymphoproliferative disorder and supports the infusion of LMP-Ts as adjuvant therapy to improve outcomes in the posttransplantation setting. These trials were registered at www.clinicaltrials.gov as #NCT00062868 and #NCT01956084.
科研通智能强力驱动
Strongly Powered by AbleSci AI